Tag: AstraZeneca

AstraZeneca will invest $90 million in India during the next five years

Leading global science-led biopharmaceutical company AstraZeneca announced its decision of further investing $90 million over the next 5 years in India.

AstraZeneca and SKOLKOVO launched Startup Challenge 2018 acceleration program

AstraZeneca and SKOLKOVO Foundation announced the launch of a joint acceleration program for projects in the area of oncology, cardiovascular, metabolic, kidney, respiratory, and autoimmune diseases.

Compugen signs an agreement with biologics R&D arm of AstraZeneca

Compugen Ltd., a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced it entered into an exclusive license agreement with MedImmune.

AstraZeneca’s hyperkalaemia drug is approved in the EU

AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma for the treatment of adults with hyperkalaemia.

EMA accepted the submission for AstraZeneca’s diabetes drug

AstraZeneca announced that the European Medicines Agency has accepted the Marketing Authorisation Variation for Forxiga (dapagliflozin) for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D).

Viela Bio spins out from AstraZeneca as an independent biotech company

Viela Bio announced that it has incorporated as an independent inflammation- and autoimmunity-focused biotechnology company after spinning out from MedImmune, the global biologics research and development arm of AstraZeneca.

Pelago Bioscience started a new research collaboration with AstraZeneca

Pelago Bioscience AB has entered into a new strategic research collaboration and license agreement with AstraZeneca. In the last two years, the companies have collaborated on numerous Cellular Thermal...

Ionis Pharmaceuticals licenses a new renal drug to AstraZeneca

drug development
Ionis Pharmaceuticals, Inc. announced that it has licensed AZD2373 to the global, science-led biopharmaceutical company AstraZeneca. AstraZeneca will be responsible for developing and commercializing the drug.

AstraZeneca and IIDF sign a memorandum of collaboration

AstraZeneca, an international biopharmaceutical company, and the Internet Initiatives Development Fund (IIDF) signed a Memorandum of Intent to collaborate in the area of digital solutions for the pharmaceutical industry

GlobalData expects that Merck will set to lead licensing deals in 2018

Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData

Array Biopharma takes legal steps against AstraZeneca

pills and money
Array Biopharma Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs, is suing AstraZeneca over royalties for a cancer drug

Syndax entered a clinicial trial collaboration with AstraZeneca

drug development
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca

Innate Pharma and MedImmune started a new clinical trial collaboration

cancer lab diagnostic
Innate Pharma announced that it has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca

The University of Geneva and AstraZeneca manage a new research project

microbiology plates
The research project DRIVE-AB has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years

Cambrex and AstraZeneca entered a long-term manufacturing agreement

Cambrex Corporation held an opening ceremony with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies

AstraZeneca obtained EU approval for its asthma drug

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Commission has approved Fasenra